surmount-1 trial tirzepatide non-diabetic obesity weight loss SURMOUNT-5: Bests Semaglutide in Head-to-Head Tirzepatide after intensive lifestyle intervention

Studies suggest that people with CFS usually have significantly lower glutathione levels, contributing to fatigue and weakened immunity

Plozasiran Now Available in China: A Once-Every-3-Month siRNA Therapy for Familial Chylomicronemia Syndrome (FCS) Plozasiran now available in China marks a milestone for FCS patients, offering a new APOC3-targeted siRNA therapy to help lower triglyceride (TG) levels in adults Ciprocopan Approved in China as the Worlds First Once-Daily Oral CFB Inhibitor for PNH Ciprocopan approved in China as the worlds first once-daily oral Complement Factor B (CFB) inhibitor, bringing a new oral treatment option for patients with paroxysmal Oveporexton Approved First in China: The First OX2R Agonist Targeting the Underlying Mechanism of Type 1 Narcolepsy Oveporexton approved first in China, becoming the worlds first approved selective orexin receptor 2 (OX2R) agonist and the first therapy designed to target the underlying Gene Therapy for Beta Thalassemia: Can CRISPR and Gene Addition Achieve Transfusion Independence

Single-Use Only (unless labeled Multi-Dose): Prevent infection by using each vial/syringe for only one patient, unless specifically approved for multi-use

These effects help patients control their blood sugar

What precautions should a smoker with type 2 diabetes take when using Ozempic